CN109055547B - Biomarker for evaluating aortic dissection risk and application thereof - Google Patents

Abstract

The invention discloses a group of biomarkers for evaluating aortic dissection risk, wherein the biomarkers are selected from a combination of one or more gene mutation sites in table 1. Furthermore, the invention provides application of the gene mutation site in preparing a detection product for detecting or evaluating aortic dissection diseases. The invention discovers 44 aortic dissection susceptibility mutation sites and researches the application prospect of the aortic dissection early prediction, and the aortic dissection related gene sites provided by the invention can be used as the early biomarker of the aortic dissection, thereby providing a new direction for further researching the genetic molecular mechanism of the aortic dissection and exploring the drug target for the early prevention and treatment of the aortic dissection.

Description

Biomarker for evaluating aortic dissection risk and application thereof

Technical Field

The invention relates to the technical field of detection in the field of biomedicine, in particular to a group of biomarkers for evaluating aortic dissection risk and application thereof.

Background

Aortic Dissection (AD) refers to a state in which two true and false Aortic lumens coexist due to the fact that the aorta is subjected to a series of external factors (such as hypertension, trauma and the like) and the Aortic intima is ruptured or not due to the presence or absence of lesion in the Aortic wall, blood enters the middle layer of the Aortic wall from the ruptured Aortic intima, and the middle layer of the aorta is continuously torn and longitudinally separated. The aortic dissection has a rapid onset, rapid development and a violent prognosis. Despite the ongoing improvement of various current therapies, the morbidity and mortality of AD remains high and, if not properly and timely treated, the mortality of AD is extremely high. Approximately 20% of AD patients are reported to die before hospital arrival, while 30% die during hospitalization. At present, an effective medicine intervention means is lacking clinically for AD, mainly surgical operation is adopted for vascular replacement, intervention operation is adopted for aortic stent implantation in an aorta cavity, and the two are combined for application, but the operation risk is high, the cost is high, and the long-term recurrence rate and the reoperation rate are still high. With the progress of imaging technology and medical equipment conditions, the detection rate of AD diseases is on the rise, and the research on the occurrence and pathogenesis of AD is also going on. The mechanism of AD production is closely related to genetics. AD related susceptibility genes are the hotspot of current AD genetics research, and the analysis of the AD related susceptibility genes is significant from the gene perspective.

Along with the completion of human genome sequencing plans and the development of high-throughput sequencing technologies, researchers in the medical field have deeper understanding on human genomes, gradually deepen understanding on disease-related genetic variation, functions of related genes and regulation and control networks, and wide application of high-throughput sequencing. The Whole Exon Sequencing (WES) technology is to capture the Whole exon region DNA by using an exon capture kit, and then perform high throughput Sequencing, and is a very mature part in current genomics research. In the last two years, literature reports on the use of WES technology for the study of complex diseases began to emerge, showing the great advantages of this technology. WES analysis of 102 patients with thoracic aortic aneurysm and AD by Ziganshin BA et al revealed that 21.6% of patients had mutations in 1 or more of the other genes and 3.9% of patients had deleterious mutations in FBN1, COL5A1, MYLK, and FLNA genes. We performed the 45 intracranial aneurysm patients in Janice l, Farlow et al and found that there were variations in 68 genes and the expression of TMEM132B gene was significantly different in patients and controls (44VS 16). Indicating that rare variations can be identified in common complex diseases by high throughput sequencing. Moreover, there is increasing evidence that rare variations have moderate to intense effects on common disease predispositions, accounting for a large proportion of genetic deletions. The limitation of rare mutations (MAF < 1% or 5%) and high cost, time cost. Genome wide association assays (GWAS) can only identify common variants (CV: MAF > 5%) and ignore certain unknown functional candidate genes that are associated with the onset of AD. Compared with Whole Genome Sequencing (WGS) and GWS, WES has the advantages of high-depth Sequencing of a Genome coding region, capability of finding low-frequency mutation and rare mutation besides deletion repetition and mutation of a large segment, wider identification range, low cost and high efficiency, is one of the most common methods for finding disease susceptibility genes or sites, particularly finding new susceptibility genes or sites, and can make up the defect that GWS cannot screen unknown candidate genes.

The AD blood vessel has high risk, is not easy to find early, has limited positive rate based on the genetic diagnosis of the known pathogenic gene, is difficult to evaluate early risk, and urgently needs to find a new molecular marker.

Disclosure of Invention

In order to solve the above problems, the present invention aims to provide a set of biomarkers for assessing aortic dissection risk, wherein the biomarkers are selected from the group consisting of one or more gene mutation sites in table 1.

Furthermore, the invention provides application of the gene mutation site in preparation of a reagent for detecting aortic dissection diseases.

Furthermore, the invention also provides application of the gene mutation site in preparing a detection kit for evaluating the risk of aortic dissection diseases.

Furthermore, the invention provides application of the gene mutation site in preparing a device for detecting aortic dissection diseases.

Preferably, the detection device is a sequencing chip.

Still further, the present invention provides a test kit for evaluating aortic dissection risk, which comprises a reagent for detecting whether mutation occurs at a mutation site of a gene described in table 1.

Preferably, the reagent comprises a primer, dNTPs, Taq enzyme and Mg for specifically amplifying the mutation site of the gene in the table 1 ²⁺And PCR reaction buffer.

Preferably, the kit may be a reagent for detecting a mutation using any technique known in the art, as long as it can detect the presence or absence of a mutation at a gene mutation site in a sample, the gene mutation site being shown in table 1. Including but not limited to the embodiments listed below.

The mutation sites of IPO4_ c.1342C > G _ p.P448A and CCDC88B _ c.1307C > G _ p.S436C genes in Table 1 are taken as examples.

In a first embodiment, the kit comprises reagents for detecting the presence of a mutation site IPO4_ c.1342c > G _ p.p448a site G allele associated with aortic dissection and/or the presence of a susceptible mutation site CCDC88B _ c.1307c > G _ p.s436c site G allele in a sample using a sequencing method. The sequencing method is a technique known in the art, and reagents such as required primers can be selected by a person of ordinary skill in the art according to needs (see the relevant instructions of the sequencer of ABI, Beckman, etc.), and will not be described herein. By using the kit, the sequence of the IPO4_ c.1342C > G _ p.P448A and/or CCDC88B _ c.1307C > G _ p.S436C mutation site related to the aortic dissection in a sample can be directly measured by a sequencing method, so that whether the mutation site carries the allelic variation of the corresponding site or not is judged, and the susceptibility of the aortic dissection is judged.

In a second embodiment, the kit comprises reagents for detecting the aortic dissection-associated mutation sites IPO4_ c.1342c > G _ p.p448a and/or CCDC88B _ c.1307c > G _ p.s436c genotype in a sample using a Taqman probe mutation assay. Wherein the Taqman probe is designed aiming at IPO4_ c.1342C > G _ p.P448A and/or CCDC88B _ c.1307C > G _ p.S436C mutation sites, and the probe can be provided by reagent companies; it can also be designed by software, such as Beacon Designer 7.5 from PREMIERBiosoft.

In a third embodiment, the kit is a kit for detecting the genotype of the IPO4_ c.1342c > G _ p.p448a and/or CCDC88B _ c.1307c > G _ p.s436c mutation site in a sample by using a PCR-single strand conformation polymorphism method. The kit comprises primers for amplifying IPO4_ c.1342C > G _ p.P448A and/or CCDC88B _ c.1307C > G _ p.S436C mutation sites, PCR reagents, a control sample and reagents required for electrophoresis of conformation detection. The electrophoresis is preferably native polyacrylamide gel electrophoresis. The control sample comprises at least one of a negative control sample of a mutation site IPO4_ c.1342C > G _ p.P448A CC homozygote and a positive control sample of a site GG homozygote, and can also comprise at least one of a negative control sample of a susceptible mutation site CCDC88B _ c.1307C > G _ p.S436C CC homozygote and a positive control sample of a site GG homozygote, and can also comprise a control sample which does not comprise a corresponding heterozygote. Preferably, the three types of control samples are included simultaneously. And (3) simultaneously carrying out electrophoresis on the amplification product of the sample to be detected and the amplification product of the control sample, and comparing the electrophoresis results to obtain the detection result of whether the sample to be detected carries the corresponding allelic variation.

Still further, the present invention provides a screening method for screening a mutation site associated with aortic dissection disease, comprising the steps of:

(1) extracting DNA of peripheral blood samples of aortic dissection patients and normal controls;

(2) carrying out ultrasonic fragmentation on DNA, breaking the tail end of a fragment for filling, adding A at the 3' end, connecting an adaptor, and selecting the fragment of 350-400 bp to prepare a whole genome library;

(3) carrying out whole exon detection by using a GenCap liquid phase capture target gene technology; performing double-end sequencing by using a high-throughput sequencer, wherein the read length is 100 bp;

(4) after exon sequencing, performing conventional filtration analysis, and taking hg19 and db mutation (v147) as reference genome versions as screening filtration standards; leaving pathogenic sites, wherein the frequency of normal people is below 5 percent, and the synonymous mutation pathogenic sites reported in the literature; in order to more accurately screen disease-related sites, SIFT, Polyphen2, mutationTaster and GERP + + mutations which are all benign are filtered; filtering indels of Mutcount >5, MutRatio > 30% and MAF > 1% in a normal database;

(5) eliminating false positive sites, namely checking and verifying a bam file (rmdup. sorted. bam) subjected to redundancy duplicate removal through IGV software, and regarding the bam file as a false positive site if mutation conditions are inconsistent; and meanwhile, the bam file is checked through samtools software. Then, rare mutation load (RVB) analysis was performed using the mutated gene (a) and the mutated site (b) as markers, respectively, and the number of samples of the gene mutation in the case group and the control group was counted and OR value, OR >1, P <0.01, was calculated. Finding that a plurality of mutation points are statistically associated with AD;

(6) Through the annotation analysis of gene functions and related channels and the deep analysis of sequencing results by literature retrieval data, the inventors finally screened 44 mutation sites related to aortic dissection.

The invention has the beneficial effects that:

the invention discovers 44 gene mutation sites related to aortic dissection and researches the application prospect of the gene mutation sites in the early prediction of aortic dissection, and the gene mutation sites related to aortic dissection provided by the invention can be used as early biomarkers of aortic dissection, thereby providing a new direction for further researching the genetic molecular mechanism of aortic dissection and exploring drug targets for early prevention and treatment of aortic dissection.

Drawings

FIG. 144 shows that GO (molecular μ Lar Function) pathway selection at sites includes two or more genes, and the pathway with p value less than or equal to 0.05 is mapped to enrichment scores;

in FIG. 244 sites GO (biological Process) selected pathways including two or more genes, pathways with p value less than or equal to 0.05, were plotted against enrichment scores.

Detailed Description

The following examples are intended to illustrate the invention, but are not intended to limit the scope of the invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the reagents used are commercially available.

The experimental procedures, for which specific conditions are not indicated in the examples, are generally conventional in the art, e.g. according to conventional conditions such as those described in Sambrook et al, molecular cloning, A laboratory Manual (third edition) (scientific Press, 2002), or according to conditions recommended by the reagent manufacturers.

EXAMPLE 1 sample Collection

From 2017, month 1 to 2018, month 4 at shenzhen, grandson, and xian cardiovascular hospital 99 patients diagnosed with Stanford type a aortic dissection through aortic CTA, collected 2mL whole blood and 590 normal control samples from the database retrieved by mekino sequencing company. Informed consent was obtained from the patients and approved by the ethical committee.

Sample treatment: mixing EDTA anticoagulated whole blood with Trizol at a ratio of 1:1, mixing well, placing in 1.8mL cell freezing tube, rapidly cooling in liquid nitrogen for 30s, and storing in refrigerator at-80 deg.C.

Example 2 extraction of blood sample DNA

(1) Adding 1mL of cell lysis solution into 1mL of blood anticoagulated by EDTA (0.01M, China, Huamei bioengineerer), gently inverting and mixing for 6 times, centrifuging at 3600rpm for 5min, and removing supernatant;

(2) pouring 1mLCL cell lysis solution into the centrifugal tube again, gently inverting and mixing uniformly for 6 times, centrifuging for 5min at the rotating speed of 3600rpm, and removing supernatant; on the premise of ensuring that the precipitate is remained in the tube, inverting the centrifugal tube on clean absorbent paper and standing for 2 min;

(3) Preparing a mixed solution of proteinase K and a buffer FG;

(4) adding 500 mu L of mixed solution of proteinase K and buffer FG, and uniformly mixing until the solution has no lumps;

(5) water bath at 65 deg.C for 30min, and mixing by reversing for several times;

(6) adding 1mL of isopropanol, and then reversing and uniformly mixing until clustered or filamentous genome DNA appears;

(7) centrifuging at 3600rpm for 8min, and removing supernatant; on the premise of ensuring that the precipitate is remained in the tube, inverting the centrifugal tube on clean absorbent paper and standing for 2 min;

(8) adding 1mL of 70% ethanol, oscillating for 5sec, centrifuging for 3min at the rotating speed of 3600rpm, and removing supernatant;

(9) repeating the step (8);

(10) on the premise of ensuring that the precipitate is remained in the tube, inverting the centrifugal tube on clean absorbent paper and standing for 5 min;

(11) at normal temperature, drying the genomic DNA sediment in air until all liquid is completely volatilized (at least 5min), oscillating for 5sec, centrifuging for 3min at the rotating speed of 3600rpm, and discarding the supernatant;

(12) adding 200 mu LTB buffer solution, carrying out low-speed vortex oscillation for 5sec, heating in water bath at 65 ℃ for 1h, and flicking to aid dissolution for several times;

(13) the concentration and purity of the extracted genomic DNA was determined using NanoDrop ND8000(THERMO, USA). The genomic DNA sample with the concentration more than 30 ng/mu L, the OD260/OD280 more than 1.8 and less than 2.0 and the total amount more than 3 mu g is regarded as qualified and stored in a refrigerator at the temperature of 80 ℃ below zero for later use;

(14) On the basis of the primary DNA quantification, agarose gel electrophoresis detection (gel concentration: 0.8%, voltage: 120V, time: 20min) is further adopted to accurately quantify the DNA. If a strong band appears after electrophoresis, the quality of the extracted DNA is higher. The sequencing of the whole exon requires that the concentration of DNA is more than or equal to 50 ng/mu L, the total amount is not less than 5 mu g, the OD260/280 is between 1.8 and 2.0, the OD260/230 is about 2.0, and a sample has no RNA pollution and no degradation or slight degradation.

Example 3 sequencing of Whole exons

1. DNA library construction

And (3) carrying out ultrasonic fragmentation on 3 mu g of DNA, breaking the tail end of the fragment for filling, adding A at the 3' end, connecting an adaptor, and selecting the fragment of 350-400 bp to prepare a whole genome library. Library samples were quality controlled using an Agilent2100 bioanalyzer (Agilent technologies, USA).

2. Target region Capture sequencing

The GenCap liquid phase capture target gene technology (Beijing Makino company) is applied to carry out the detection of the whole exon. Mu.g of the DNA library was mixed with BL buffer and probe, heated at 95 ℃ for 7min, heated at 65 ℃ for 2min, 23. mu.L of HY buffer preheated to 65 ℃ was added, and hybridization was carried out at 65 ℃ for 22 h. 50 μ L of MyOne magnetic beads (Life Technology, USA) were washed 3 times with 500 μ L of 1 Xbinding buffer and resuspended in 80 μ L of 1 Xbinding buffer. Add 64. mu.L of 2 Xbinding buffer to the hybridization mixture and transfer to a tube containing 80. mu.L of MyOne magnetic beads. And (5) uniformly mixing for 1h by rotation. The beads were washed with WB1 buffer at room temperature for 15min and with WB3 buffer at 65 ℃ for 3 times, each for 15 min. The bound DNA is then eluted with an elution buffer. The eluted DNA was subjected to PCR reaction under the following conditions: pre-denaturation at 98 ℃ for 30 s; denaturation at 98 ℃ for 25s, annealing at 65 ℃ for 30s, and extension at 72 ℃ for 30s, for 15 cycles; finally, extension is carried out for 5min at 72 ℃. PCR products were purified using SPRIbeads (Beckman Co. mu. Lter, USA) according to the product instructions. The enriched library was paired-end sequenced using an illumina HiSeq 2000 sequencer, reading 100 bp.

3. Data analysis

The original sequencing sequence obtained by sequencing contains low-quality reads with connectors, and can interfere with subsequent information analysis. To ensure the quality of the information analysis, the raw data was filtered with Cutadapt software, the sequencing data with linker sequences removed and low quality bases removed was aligned with Burrows-Wheeler Aligner (BWA) to the human genome (version GRCh37/hg19), and redundancy was removed with the Picard tool. The depth of the target area is calculated using the coverageBed tool. And (3) carrying out re-alignment on the position close to the indel site through GATK software so as to improve the quality of the sequence. The GATK HaplotpyeCaller detects Mutation and indel Mutation information and annotates the mutations with ANNOVAR, and the annotation databases include db Mutation 147,1000 genes project, exterior sequencing project (ESP6500), Inhouse Database (MyGenosics), gnomaD _ Gene _ EAS, Online Mendelian Inheritance Database in Man (OMIM) and Human Gene Mutation Database (HGMD Professional 2016.10). The pathogenicity prediction database includes SIFT, PolyPhen-2 and MutationTaster, and the pathogenicity is classified by the ACMG standard guidelines.

4. Variant filtration

To find out potential pathogenic mutations, data need to be filtered. Mainly directed to mutations in exon regions and variable splicing regions, first step: leaving behind a pathogenic mutation (pathogenic) site in the pathogenicity assay (pathogenic _ analysis). The filtration screening criteria were as follows:

The second step: screening sites which are not present or less than 5% of five normal human mutation databases, wherein the sequencing frequency of the mutation bases is more than 5, the mutation frequency is more than or equal to 30%, 1000g2015apr, ESP6500si, Inhouse, ExAC _ ALL and ExAC _ EAS are reserved; synonymous mutation sites in the dataset were removed, and additional mutation sites were left as reported in the literature.

5. Statistical analysis

Rare mutation load analysis is carried out on the filtered mutation results, data of 590 Mekenol cases are selected as a control sample, the OR value and the 95% confidence interval are analyzed by utilizing Metabin in R language, and a statistical test is carried out by using a Mantel-Haenszel's method, and the fact that the p value is less than 0.01 is considered to be remarkable.

6. As a result, the

After exon sequencing, conventional filtration analysis was performed, screening filtration criteria: hg19, db mutation (v147) were used as reference genome versions. Leaving pathogenic (pathogenic) sites, normal human frequency below 5%, and the reported synonymous mutation pathogenic site in literature, to obtain 59351 point mutation. In order to more accurately screen relevant disease sites, SIFT, Polyphen2, MutationTaster and GERP + + are further filtered to predict all benign mutations; filtering Indel with Mutcount >5, MutRItio > 30% and MAF > 1% in a normal database; 29979 point mutations were obtained by the above screening.

Then, the inventor carries out the elimination work of false positive sites, firstly, checking and verifying the bam files (rmdup. sorted. bam) after redundancy duplicates are removed through IGV software, and regarding the bam files as false positive sites if mutation conditions are inconsistent; while the bam file is viewed by samtools software. Then, using the mutated gene (a) and the mutated site (b) as markers, respectively, to perform rare mutation load (RVB) analysis, counting the number of samples of the gene mutation in the case group and the control group, and calculating OR value, OR >1, P < 0.01. As a result, 44 mutation sites were found to be statistically correlated with AD, as shown in Table 1.

TABLE 1 mutation sites of genes associated with aortic dissection

Example 4 annotation of Gene function and related pathways

The inventors performed annotation of gene function and related pathways for the 44 selected mutation sites.

Go (gene ontology), a comprehensive database describing gene Function, which can be divided into three parts, Molecular Function (MF), Biological Process (BP), and Cell Component (CC). GO enrichment was significantly enriched with p less than 0.05.

In the annotation of the pathways of the genes with 44 mutation sites, a map with the count greater than or equal to 2 is selected, as shown in fig. 1 and 2, and in the BP (biological process) analysis, the genes with the sites are significantly enriched in the redox biological process.

The results of the screening of 44 mutation sites found that:

PTGR1_ c.655G > A _ p.G219S (OR & ltgt 55.65, 95% CI & lt2.97-1041.89), HSDL2_ c.593A & ltC _ p.D198A (OR & lt24.8, 95% CI & lt2.74-224.27), CBR4_ c. & lt87 & gt-88 delTT & ltOR & lt3.9, 95% CI & lt1.57-9.67) are sites related to the redox process.

BID _ c.214C > T _ p.R72C (OR is 24.8, 95% CI is 2.74-224.27), DAZAP1_ c.276 delG- (OR is 12.38, 95% CI is 2.24-68.52), SETMAR _ c.1025G > T _ p.S342I (OR is 7.55, 95% CI is 2.26-25.23) and site mutation related to cell migration and differentiation. Proliferation, migration, and differentiation of vascular endothelial cells can lead to changes in vascular endothelial morphology, which may be associated with changes in vascular intimal morphology in AD. And LAD1_ c.430C > T _ p.R144W (OR 8.24, 95% CI 1.82-37.39) is related to cadherin, and vascular endothelial cell cadherin has a certain relation with arterial diseases.

CYBRD1_ c.293T > C _ p.M98T (OR is 31.33, 95% CI is 3.62-271.13), PCDH12_ c.728C > T _ p.A243V (OR is 12.38, 95% CI is 2.24-68.52), ZNF717_ c.1498A > G _ p.T500A (OR is 4.16, 95% CI is 1.45-11.97) are related to the combination of metal ions. Metal ions are closely linked to vascular tone, which may be linked to AD by affecting blood pressure.

PLA2G7_ c 81 — 78 delTGTG- (OR 38, 95% CI 4.52-319.21), ITCH _ c.385a > G _ p.t129a (OR 15.64, 95% CI 2.99-81.77), PKHD1_ c.11525g > a _ p.r3842q (OR 12.38, 95% CI 2.24-68.52), CAMP _ c.154c > T _ p.r52w (OR 8.24, 95% CI 1.82-37.39) may be involved in processes such as lipid metabolism, oxidative stress, inflammatory reaction, platelet activating factor metabolism, and the like.

EXAMPLE 5 preparation of early diagnosis kit for predicting aortic dissection disease

The kit for aortic dissection according to the present invention may include a primer reagent that specifically amplifies 1 or more gene sites in table 1.

The following 4 schemes are provided:

kit 1: the kit comprises a primer pair for specifically amplifying a nucleotide sequence within a CCDC88B _ c.1307C > G _ p.S436C site, which is shown as SEQ ID NO:1 and SEQ ID NO: 2.

And (3) a kit 2: the kit comprises a primer pair for specifically amplifying nucleotide sequences within IPO4_ c.1342C > G _ p.P448A sites, which is shown as SEQ ID NO. 3 and SEQ ID NO. 4.

Kit 3: the kit comprises a primer pair for specifically amplifying nucleotide sequences including CPNE9_ c.260T > C: p.V87A sites, which is shown as SEQ ID NO. 5 and SEQ ID NO. 6.

Kit 4: the kit comprises a primer pair for specifically amplifying nucleotide sequences within CCDC88B _ c.1307C > G _ p.S436C sites as shown in SEQ ID NO 1 and SEQ ID NO 2, a primer pair for amplifying nucleotide sequences within IPO4_ c.1342C > G _ p.P448A sites as shown in SEQ ID NO 3 and SEQ ID NO 4, and a primer pair for amplifying nucleotide sequences within CPNE9_ c.260T > C: p.V87A sites as shown in SEQ ID NO 5 and SEQ ID NO 6.

The amplification primers are as follows:

CCDC88B_c.1307C>G_p.S436C:

SEQ ID NO:15’-GCTGGCTGAGGAGAATGTGG-3’,

SEQ ID NO:25’-TGAGGGCTGTGGTCGAAGG-3’；

IPO4_c.1342C>G_p.P448A:

SEQ ID NO:35’-CCATATCAGCAGCTATTCAAGG-3’,

SEQ ID NO:45’-CGCAAGTCAGGGTCGTCTA-3’；

CPNE9_c.260T>C:p.V87A:

SEQ ID NO:55’-CCCGGCCACCAAGATTGAA-3’,

SEQ ID NO:65’-GTGAGGGTTCGCTCTACTCG-3’。

the kit also comprises PCR reagents, a control sample and reagents required for electrophoresis for detecting conformation. The usual reagents required for PCR technology, such as: dNTPs, MgCl₂Double distilled water, Taq enzyme, and the like. The electrophoresis is preferably native polyacrylamide gel electrophoresis. In addition, there may be a standard and a control (e.g., a genotype-determining standard and a blank control). The amplification product of the sample to be tested and the amplification product of the control sample are electrophoresed simultaneously, and the comparison of the electrophoresis results can be performedAnd obtaining the detection result of whether the sample to be detected carries the corresponding allelic variation.

The kit has the value that only peripheral blood is needed without other tissue samples, mutation is detected through the simplest and most specific primer pair, and then the aortic dissection is judged in an auxiliary mode through a mutation spectrum, so that the kit is stable, convenient and accurate to detect, and greatly improves the sensitivity and specificity of disease diagnosis, and therefore the kit can help to guide diagnosis and more effective individualized treatment when put into practice.

Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Sequence listing

<110> Wangzanxin

<120> a group of biomarkers for evaluating aortic dissection risk and application thereof

<130> p18053

<160> 6

<170> SIPOSequenceListing 1.0

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 1

gctggctgag gagaatgtgg 20

<210> 2

<211> 19

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 2

tgagggctgt ggtcgaagg 19

<210> 3

<211> 22

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 3

ccatatcagc agctattcaa gg 22

<210> 4

<211> 19

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 4

cgcaagtcag ggtcgtcta 19

<210> 5

<211> 19

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 5

cccggccacc aagattgaa 19

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 6

gtgagggttc gctctactcg 20

Claims (1)

1. The application of the detection reagent of the aortic dissection susceptibility SNP site in preparing a kit for predicting the risk of Stanford A-type aortic dissection diseases comprises the detection reagent of whether the aortic dissection susceptibility SNP site generates mutation, and the SNP sites are BID _ c.214C > T _ p.R72C, HSDL2_ c.593A > C _ p.D198A and PTGR1_ c.655G > A _ p.G219S.

Images